Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 16, 2004, Pages 3972-3990

  Rao, P N Praveen ^a   Uddin, Md Jashim ^a   Knaus, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3,4,6 TRIPHENYLPYRAN 2 ONE DERIVATIVE; 6 (4 METHOXYPHENYL) 3 (4 METHANESULFONYLPHENYL) 4 PHENYLPYRAN 2 ONE; ARGININE; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLYCINE; ISOLEUCINE; LEUCINE; METHIONINE; PHENYLALANINE; PYRAN DERIVATIVE; ROFECOXIB; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VALINE;

ABDOMINAL PAIN; ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; INHIBITION KINETICS; NONHUMAN; ORIENTATION; PAW EDEMA; PROTEIN INTERACTION; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANALGESICS; ANIMALS; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EDEMA; ISOENZYMES; MEMBRANE PROTEINS; MODELS, MOLECULAR; PAIN MEASUREMENT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRANS; PYRONES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 3242748214     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049939b     Document Type: Article

References (41)

1. 2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 1990, 265, 16737-16740.
2. Xie, W. L.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of mitogen-responsive gene encoding prostaglandin synthesis is regulated by mRNA splicing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696.
3. Vane, J. R.; Bakhle, Y. S.; Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998, 38, 97-120.
4. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Group comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000, 343, 1520-1528.
5. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W. F.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000, 284, 1247-1255.
6. Subbaramaiah, K.; Dannenberg, A. J. Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 2003, 24, 96-102.
7. Fujita, H.; Koshida, K.; Keller, E. T.; Takahashi, Y.; Yoshimito, T.; Namiki, M.; Mizokami, A. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002, 53, 232-240.
8. Xiang, Z.; Ho, L.; Yemul, S.; Zhao, Z.; Qing, W.; Pompl, P.; Kelley, K.; Dang, A.; Qing, W.; Teplow, D.; Pasinetti, G. M. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 2002, 10, 271-278.
9. Teismann, P.; Tieu, K.; Choi, D. K.; Wu, D. C.; Naini, A.; Hunot, S.; Vila, M.; Jackson-Lewis, V.; Przedborski, S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U S A. 2003, 100, 5473-5478.
10. Talley, J. J. Selective inhibitors of cyclooxygenase-2 (COX-2). Prog. Med. Chem. Res. 1999, 36, 201-234.
11. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
12. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, [MK 966, VIOXX, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
13. Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
14. Friesen, R. W.; Brideau, C.; Chan, C. C.; Charleson, S.; Deschenes, D.; Dube, D.; Ethier, D.; Fortin, R.; Gauthier, J. Y.; Girard, Y.; Gordon, R.; Greig, G. M.; Riendeau, D.; Savoie, C.; Wang, Z.; Wong, E.; Visco, D.; Xu, L. J.; Young, R. N. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2777-2782.
15. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, D.; Falgueyret, J. P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, J.; Mancini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girard, Y.; Prasit, P.; Zamboni, R.; Rodger, I. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C. C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
16. Marrison, L. R.; Dickinson, J. M.; Fairlamb, I. J. Bioactive 4-substituted-6-methyl-2-pyrones with promising cytotoxicity against A2780 and K562 cell lines. Bioorg. Med. Chem. Lett. 2002, 12, 3509-3513.
17. Marrison, L. R.; Dickinson, J. M.; Fairlamb, I. J. Suzuki cross-coupling approaches to the synthesis of bioactive 3-substituted and 5-substituted-4- methoxy-6-methyl-2-pyrones. Bioorg. Med. Chem. Lett. 2003, 13, 2667-2671.
18. Tummino, P. J.; Prasad, J. V.; Ferguson, D.; Nouhan, C.; Graham, N.; Domagala, J. M.; Ellsworth, E.; Gajda, C.; Hagen, S. E.; Lunney, E. A.; Para, K. S.; Tait, B. D.; Pavlovsky, A.; Erickson, J. W.; Gracheck, S.; McQuade, T. J.; Hupe, D. J. Discovery and optimization of nonpeptide HIV-1 protease inhibitors. Bioorg. Med. Chem. 1996, 4, 1401-1410.
19. Rao, P. N. P.; Amini, A.; Li, H.; Habeeb, A. G.; Knaus, E. E. Design, synthesis and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl) -4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2003, 46, 4872-4882.
20. Li, C. S.; Lau, C. K.; Therien, M.; Prasit, P. Pyrones as inhibitors of cyclooxygenase-2. World Patent WO 02/02547, 10 January, 2002, Chem. Abstr. 136, 85758.
21. Crespo, C.; Isabel, M.; Mayorga, J.; Miguel, J.; Pueyo, S. L. 4-Phenylpyran-2-one derivatives. World Patent WO 03/006451 A1, 23 January, 2003; Chem. Abstr. 138, 122549.
22. Baddar, F. G.; Al-Hajjar, F. H.; El-Rayyes, N. R. Acetylenic ketones I. Reaction of aroylphenylacetylenes with compounds containing an active methylene group. J. Heterocyl. Chem. 1976, 13, 195-203.
23. Henry, W. P.; Hughes, R. P. Organic synthesis using carbon monoxide. regiospecific cobalt-mediated synthesis of 2H-pyran-2-ones. J. Am. Chem. Soc. 1986, 108, 7862-7864.
24. Hirano, K.; Minakata, S.; Komatsu, M. Unusual fluorescent properties of novel fluorophores, 6-aryl-3,4-diphenyl-αpyrone derivatives. Bull. Chem. Soc. Jpn. 2001, 74, 1567-1575.
25. 4-mediated nucleophilic substitution of propargylic esters. Tetrahedron 2000, 56, 7463-7468.
26. Chowdhury, C.; Kundu, N.G. Studies on copper(I) catalysed cross-coupling reactions: a convenient and facile method for the synthesis of diversely substituted α,β-acetylenic ketones. Tetrahedron 1999, 55, 7011-7016.
27. Habeeb, A. G.; Rao, P. N. P.; Knaus, E. E. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. J. Med. Chem. 2001, 44, 3039-3042.
28. Rahim, M. A.; Rao, P. N. P.; Knaus, E. E. Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 2753-2756.
29. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature 1996, 384, 644-648.
30. 523 → Val mutation. J. Biol. Chem. 1997, 272, 9280-9286.
31. Greig, G. M.; Francis, D. A.; Falgueyret, J. P.; Ouellet, M. M.; Percival, M. D.; Roy, P.; Bayly, C.; Mancini, J. A.; O'Neill, G. P. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal antimflammatory drugs. Mol. Pharmacol. 1997, 52, 829-838.
32. Hood, W. F.; Gierse, J. K.; Isakson, P. C.; Kiefer, J. R.; Kurumbail, R. G.; Seibert, K.; Monahan, J. B. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol. Pharmacol. 2003, 63, 870-877.
33. 3N: simple, mild and efficient preparation of propargylic alcohols. Tetrahedron Lett. 2002, 43, 8323-8325.
34. Kundu, N. G.; Pal, M.; Chowdhury, C. A highly simplified approach for the synthesis of β-aryl substituted conjugated acetylenic ketones mediated through palladium-copper catalysis. J. Chem. Res. 1995, 1, 101-123.
35. Stiegman, A. E.; Graham, E.; Perry, K. J.; Khundkar, L. R.; Cheng, L. T.; Perry, J. W. The electronic structure and second-order nonlinear optical properties of donor-acceptor acetylenes: a detailed investigation of structure-property relationships. J. Am. Chem. Soc. 1991, 113, 7658-7666.
36. Coan, S. B.; Becker, E. I. Synthesis of unsymmetrical 1,3-diphenyl-2-propanones. J. Am. Chem. Soc. 1954, 76, 501-503.
37. Corse, J. W.; Jones, R. G.; Soper, Q. P.; Whitehead, C. W.; Behrens, O. K. Biosynthesis of penicillins. V. substituted phenylacetic acid derivatives as penicillin precursors. J. Am. Chem. Soc. 1948, 70, 2837-2843.
38. Noyce, D. S.; DeBruin, K. E. Kinetics and mechanism of the acid-catalyzed hydration of phenylbenzoylacetylene. J. Am. Chem. Soc. 1968, 90, 372-377.
39. Winter, C. A.; Risley, E. A.; Nuss, G. W.; Carrageenan-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 1962, 111, 544-552.
40. Kumar, P.; Knaus, E. E. Synthesis and antiinflammatory activity of N-substituted dihydropyridylacetic acids, esters and amides. Drug Des. Delivery 1987, 2, 145-149.
41. Fukawa, K.; Kawano, O.; Hibi, M.; Misaka, N.; Ohba, S.; Hatanaka, Y. Method for evaluating analgesic agents in rats. J. Pharmacol. Methods 1980, 4, 251-259.